Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs’ psychological side effects, either de novo or as exacerbations of prior psychiatric disease.
Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Case series and case reports of psychiatric complications were also reviewed.
Most studies were cross-sectional and had a control group of healthy volunteers or patients with nonfunctioning pituitary adenomas. There were few prospective studies, with/without control group, that included small numbers of patients. Compared with controls, patients with hyperprolactinemia generally had worse quality of life, anxiety, depression and certain personality traits. Patients receiving DAs had higher impulsivity scores than normoprolactinemic controls. Impulse control disorders (ICDs) were reported in both genders, with hypersexuality mostly in men. Multiple ICDs were sometimes reported in the same patient, usually reversible after DA discontinuation. In case reports, DA therapy was temporally associated with severe depression, manic episodes or psychosis, which improved after discontinuation and administration of psychiatric medications. Gender type of DA, dose and duration of therapy did not correlate with occurrence of psychiatric pathology.
Patients with hyperprolactinemia receiving DAs may develop changes in mood and behavior regardless of prior psychiatric history. Increased awareness for ICDs, depression, mania and other types of psychosis is needed by all physicians who prescribe DAs. Larger prospective controlled clinical studies are needed to delineate prevalence, risk stratification and management.
MelmedSCasanuevaFFHoffmanARKleinbergDLMontoriVMSchlechteJAWassJAEndocrineS.Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism201196273–288. (https://doi.org/10.1210/jc.2010-1692)
Grall-BronnecMVictorri-VigneauCDonnioYLeboucherJRousseletMThiabaudEZreikaNDerkinderenPChallet-BoujuG.Dopamine agonists and impulse control disorders: a complex association. Drug Safety20184119–75. (https://doi.org/10.1007/s40264-017-0590-6)
GhahremaniDGLeeBRobertsonCLTabibniaGMorganATDe ShetlerNBrownAKMonterossoJRAronARMandelkernMAet al. Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. Journal of Neuroscience2012327316–7324. (https://doi.org/10.1523/JNEUROSCI.4284-11.2012)
AthanasouliaAPSieversCIsingMBrockhausACYassouridisAStallaGKUhrM.Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. European Journal of Endocrinology2012167327–335. (https://doi.org/10.1530/EJE-12-0198)
ZacurHAChapanisNPLakeCRZieglerMTysonJE.Galactorrhea-amenorrhea: psychological interaction with neuroendocrine function. American Journal of Obstetrics and Gynecology1976125859–862. (https://doi.org/10.1016/0002-9378(76)90863-2)
RoccoAMoriFBaldelliRAversaAMunizziMRNardoneMRFabbriniAFalaschiP.Effect of chronic bromocriptine treatment on psychological profile of patients with PRL-secreting pituitary adenomas. Psychoneuroendocrinology19931857–66. (https://doi.org/10.1016/0306-4530(93)90055-P)
KarsMvan der KlaauwAAOnsteinCSPereiraAMRomijnJA.Quality of life is decreased in female patients treated for microprolactinoma. European Journal of Endocrinology2007157133–139. (https://doi.org/10.1530/EJE-07-0259)
AthanasouliaAPIsingMPfisterHMantzorosCSStallaGKSieversC.Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology201296204–211. (https://doi.org/10.1159/000335996)
Athanasoulia-KasparAPPoppKHStallaGK.Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist. Endocrine Connections20187R88–R94. (https://doi.org/10.1530/EC-18-0030)
van HolstRJvan den BrinkWVeltmanDJGoudriaanAE.Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neuroscience and Biobehavioral Reviews20103487–107. (https://doi.org/10.1016/j.neubiorev.2009.07.007)
DavieM.Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. Journal of Neuropsychiatry and Clinical Neurosciences200719473–474. (https://doi.org/10.1176/jnp.2007.19.4.473)
ThondamSKAlusiSO'DriscollKGilkesCECuthbertsonDJDaousiC.Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clinical Neuropharmacology201336170–172. (https://doi.org/10.1097/WNF.0b013e31829fc165)
De SousaSMChapmanIMFalhammarHTorpyDJ.Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine201755618–624. (https://doi.org/10.1007/s12020-016-1088-1)
BancosINannengaMRBostwickJMSilberMHEricksonDNippoldtTB.Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clinical Endocrinology201480863–868. (https://doi.org/10.1111/cen.12375)
MartinkovaJTrejbalovaLSasikovaMBenetinJValkovicP.Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clinical Neuropharmacology201134179–181. (https://doi.org/10.1097/WNF.0b013e3182281b2f)
BulwerCConnRShankarAFerrauFKapurSEderiesAKorbonitsMSpoudeasHA.Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clinical Endocrinology201786862–864. (https://doi.org/10.1111/cen.13339)
BarakeMEvinsAEStoeckelLPachasGNNachtigallLBMillerKKBillerBMTritosNAKlibanskiA.Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary201417150–156. (https://doi.org/10.1007/s11102-013-0480-6)
RoveraCCremaschiLThanjuAFiorentiniAMauriMCSeratiMLindenmayerJPAltamuraAC.Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. Asian Journal of Psychiatry20162294–95. (https://doi.org/10.1016/j.ajp.2016.05.010)
FreemanBLevyWGormanJM.Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. Journal of Psychiatric Practice200713120–124. (https://doi.org/10.1097/01.pra.0000265771.47153.a0)
HofferZSRothRLMathewsM.Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics200950317–324. (https://doi.org/10.1176/appi.psy.50.4.317)
BroekhofRGosselinkMJPijlHGiltayEJ.The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. General Hospital Psychiatry201234209.e1–209.e3.
Santos AndradeEHPanPMda SilvaPFGadelhaA.New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature. Case Reports in Medicine20102010573252.